• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Locust Walk Acquisition Corp.

    8/17/21 11:24:14 AM ET
    $LWAC
    Finance
    Get the next $LWAC alert in real time by email
    SC 13G 1 lf_sc13g.htm SCHEDULE 13G Schedule 13G

     

    OMB APPROVAL

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    OMB Number:3235-0145 

    Expires:Febuary 28, 2009 

    Estimated average burden
    hours per response ....10.4

     

     

    SCHEDULE 13G

    Under the Securities and Exchange Act of 1934

    (Amendment No.                 )*

     

    Locust Walk Acquisition Corp.

    (Name of Issuer)

     

    Class A Common Stock, par value $ 0.0001

    (Title of Class of Securities)

     

    54015L103

    (CUSIP Number)

     

     

    August 16, 2021

    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    o  Rule 13d-1(b)

    ý  Rule 13d-1(c)

    o  Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


    1


     

    CUSIP No    54015L103

    1.Names of Reporting Persons. 

    I.R.S. Identification Nos. of above persons (entities only). 

    Feis Equities LLC 

    2.Check the Appropriate Box if a Member of a Group 

    (a)o 

    (b)o 

    3.SEC Use Only 

    4.Citizenship or Place of OrganizationState of Illinois 

    Number of Shares Beneficially Owned by Each Reporting Person With

    5.Sole Voting Power906,661 

    6.Shared Voting Power                               0 

    7.Sole Dispositive Power906,661 

    8.Shared Dispositive Power                        0 

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 

    906,661 

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)      o 

    11.Percent of Class Represented by Amount in Row (9) 

    5.02% 

    12.Type of Reporting Person (See Instructions) 

    OO-Limited Liability Company 


    2


     

    CUSIP No.   54015L103

    1.Names of Reporting Persons. 

    I.R.S. Identification Nos. of above persons (entities only). 

    Lawrence M. Feis 

    2.Check the Appropriate Box if a Member of a Group 

    (a)o 

    (b)o 

    3.SEC Use Only 

    4.Citizenship or Place of OrganizationU.S.A. 

    Number of Shares Beneficially Owned by Each Reporting Person With

    5.Sole Voting Power906,661 

    6.Shared Voting Power                              0 

    7.Sole Dispositive Power906,661 

    8.Shared Dispositive Power                        0 

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 

    906,661 

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)      o 

    11.Percent of Class Represented by Amount in Row (9)  

    5.02% 

    12.Type of Reporting Person (See Instructions) 

    IN 


    3


     

    Item 1.

    The name and address of the principal executive offices of the Issuer are:

    Locust Walk Acquisition Corp.

    200 Clarendon Street, 51st Floor

    Boston, MA  20116

    Item 2.

    This statement on Schedule 13G is being filed by:

    (a) Name of Person Filing 

     

    (i)Feis Equities LLC 

    (ii)Lawrence M. Feis 

     

     

     

     

     

    (b)Address: 

    The address of the business office of each of the Reporting Persons is:

     

    20 North Wacker Drive

    Suite 2115

    Chicago, Illinois  60606

     

     

     

     

     

    (c)Citizenship/Place: 

    Citizenship is set forth in Row 4 of the cover page for each Reporting Person hereto and is incorporated hereto by reference for each Reporting Person.

     

    (d)Title of Class of Securities: 

    Class A common Stock, par value $ 0.0001 (the “Shares”)

     

    (e)CUSIP Number: 

    54015L103

     

     

     


    4


    Item 3.  If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

    (a)oBroker or dealer registered under section 15 of the Act (15 U.S.C. 78o). 

    (b)oBank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c). 

    (c)oInsurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c). 

    (d)oInvestment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8). 

    (e)oAn investment adviser in accordance with §240.13d-1(b)(1)(ii)(E); 

    (f)oAn employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F); 

    (g)oA parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G); 

    (h)oA savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); 

    (i)oA church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); 

    (j)oGroup, in accordance with §240.13d-1(b)(1)(ii)(J). 

    Item 4.  Ownership

     

    The information required by Items 4(a)-(c) is set forth in Rows 5-11 of the cover page for each Reporting Person and incorporated by reference herein.

     

    The percentage set forth in row 11 of the cover page for each Reporting Person is based on 18,045,000 shares of Class A common stock outstanding as of August 12, 2021, as reported by the Issuer in its Quarterly Report on Form 10-Q for the quarter ended June 30, 2021, filed with the Securities and Exchange Commission on August 12, 2021.


    5


     

    Item 5.  Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following  o

    Item 6.  Ownership of More than Five Percent on Behalf of Another Person

    Not applicable.

    Item 7.  Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company

    Not applicable.

    Item 8.  Identification and Classification of Members of the Group

    Not applicable.

    Item 9.  Notice of Dissolution of Group

    Not applicable.

    Item 10.  Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.


    6


    SIGNATURES

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date:August 17,2021 

     

     

     

     

    Date:August 17, 2021 

     

    FEIS EQUITIES LLC

    By:/s/ Lawrence M. Feis 

                Managing Member LLC

     

     

    LAWRENCE M. FEIS

    By:/s/ Lawrence M. Feis 

     


    7


     

     

    EXHIBIT INDEX

     

    Ex.

     

    Page No.

     

     

     

    A

    Joint Filing Agreement

    9


    8


     

    JOINT FILING AGREEMENT

     

    The undersigned hereby agree that the statement on Schedule 13G with respect to the Class A common stock of Locust Walk Acquisition Corp. dated as of August 17,2021 is, and any amendments thereto (including amendments on Schedule 13D) signed by each of the undersigned shall be filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended.

     

    FEIS EQUITIES LLC 

    By:/s/ Lawrence M. Feis 

    Managing Member LLC 

     

     

    LAWRENCE M. FEIS 

    By:/s/ Lawrence M. Feis 

     

    Date:  August 17, 2021


    9

    Get the next $LWAC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $LWAC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $LWAC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by Locust Walk Acquisition Corp.

      SC 13D - eFFECTOR Therapeutics, Inc. (0001828522) (Subject)

      9/13/21 6:23:36 AM ET
      $LWAC
      Finance
    • SEC Form SC 13D filed by Locust Walk Acquisition Corp.

      SC 13D - eFFECTOR Therapeutics, Inc. (0001828522) (Subject)

      9/7/21 5:12:00 PM ET
      $LWAC
      Finance
    • SEC Form SC 13D filed by Locust Walk Acquisition Corp.

      SC 13D - eFFECTOR Therapeutics, Inc. (0001828522) (Subject)

      9/3/21 4:00:25 PM ET
      $LWAC
      Finance

    $LWAC
    SEC Filings

    See more
    • Amendment: SEC Form S-1/A filed by Locust Walk Acquisition Corp.

      S-1/A - LightWave Acquisition Corp. (0002061379) (Filer)

      6/9/25 8:37:32 AM ET
      $LWAC
      Finance
    • SEC Form EFFECT filed by Locust Walk Acquisition Corp.

      EFFECT - eFFECTOR Therapeutics, Inc. (0001828522) (Filer)

      10/6/21 12:15:17 AM ET
      $LWAC
      Finance
    • SEC Form 424B3 filed by Locust Walk Acquisition Corp.

      424B3 - eFFECTOR Therapeutics, Inc. (0001828522) (Filer)

      10/5/21 4:24:26 PM ET
      $LWAC
      Finance

    $LWAC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Locust Walk Acquisition Corp.'s Stockholders Approve Business Combination with eFFECTOR Therapeutics to Create Next-Generation Oncology Company Developing New Class of Cancer Therapies

      SAN DIEGO, Aug. 24, 2021 (GLOBE NEWSWIRE) -- Locust Walk Acquisition Corp. (NASDAQ:LWAC) ("LWAC" or the "Company"), a special purpose acquisition company, announced today that the Company's stockholders have approved all proposals related to the previously announced business combination (the "Business Combination") with eFFECTOR Therapeutics, Inc. ("eFFECTOR") at a special meeting of stockholders held on August 24, 2021. Approximately 93.2% of the votes cast at the meeting on the Business Combination proposal, representing approximately 71.7% of LWAC's outstanding shares, voted to approve the Business Combination. LWAC stockholders also voted overwhelmingly to approve the other proposals

      8/24/21 4:47:39 PM ET
      $LWAC
      Finance
    • eFFECTOR Therapeutics Initiates Phase 2a Expansion Cohorts Evaluating Zotatifin in Breast Cancer and KRAS-mutant Non-small Cell Lung Cancer

      SAN DIEGO, Aug. 04, 2021 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (eFFECTOR), a leader in the development of selective translation regulation inhibitors (STRIs) for the treatment of cancer, announced today the initiation of dosing in the Phase 2a expansion portion of an ongoing Phase 1/2 trial of zotatifin (eFT226) in solid tumors. This followed conclusion of the Phase 1 dose escalation portion of the trial and selection of a recommended Phase 2 dose (RP2D). eFFECTOR expects to initiate multiple indication-specific expansion cohorts in ER+ breast cancer and KRAS-mutant non-small cell lung cancer (NSCLC). Zotatifin will be evaluated both as a single agent and in combination with targ

      8/4/21 8:00:00 AM ET
      $LWAC
      Finance
    • eFFECTOR Therapeutics Doses First Patient with COVID-19 in Phase 1b Clinical Trial Evaluating Zotatifin as a Host-Targeted Antiviral Agent

      SAN DIEGO, July 22, 2021 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulation inhibitors (STRIs) for the treatment of cancer, today announced that the first patient has been dosed in a Phase 1b trial evaluating zotatifin (eFT226) as an antiviral agent in an outpatient setting for those with mild to moderate COVID-19 disease. This study is sponsored by a $5.0 million cooperative agreement from the Defense Advanced Research Projects Agency (DARPA) and Defense Health Agency (DHA) and is being conducted in collaboration with the Quantitative Biosciences Institute (QBI) at University of California, San Francisco (UCSF). "Rising case

      7/22/21 8:00:00 AM ET
      $LWAC
      Finance

    $LWAC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Ehrlich Christopher B

      4 - eFFECTOR Therapeutics, Inc. (0001828522) (Issuer)

      10/8/21 5:22:23 PM ET
      $LWAC
      Finance
    • SEC Form 4 filed by Bhatt Elizabeth

      4 - eFFECTOR Therapeutics, Inc. (0001828522) (Issuer)

      10/8/21 5:20:18 PM ET
      $LWAC
      Finance
    • SEC Form 4 filed by Smither John W

      4 - eFFECTOR Therapeutics, Inc. (0001828522) (Issuer)

      10/8/21 5:18:52 PM ET
      $LWAC
      Finance